Segment information (Tables)

6 Months Ended

Jun. 30, 2012

Schedule of segment reporting information by segment

	Three months ended,				Six months ended
	June 30,				June 30,
	2012		2011		2012		2011

Sales revenue
Pharmaceutical distribution	$	43,505,861	$	48,493,250	$	96,767,659	$	91,744,421
Retail pharmacy		13,864,014		13,151,576		27,853,992		25,700,933
Manufacturing		3,728,085		3,470,922		7,721,668		6,273,634

	$	61,097,960	$	65,115,748	$	132,343,319	$	123,718,988

	Three months ended,				Six months ended
	June 30,				June 30,
	2012		2011		2012		2011

Operating income
Pharmaceutical distribution	$	4,649,705	$	7,769,085	$	12,526,948	$	14,328,166
Retail pharmacy		2,749,194		2,485,093		5,225,374		4,273,249
Manufacturing		1,596,813		1,774,233		3,514,913		3,244,874

	$	8,995,712	$	12,028,411	$	21,267,235	$	21,846,289

	Three months ended,					Six months ended
	June 30,					June 30,
	2012			2011		2012		2011

Depreciation and amortization expenses
Pharmaceutical distribution		$	183,757	$	122,347	$	365,141	$	292,106
Retail pharmacy			102,041		46,202		179,705		89,596
Manufacturing			123,971		160,048		268,137		311,376

		$	409,769	$	328,597	$	812,983	$	693,078

	June 30,		December 31,
	2012		2011

Assets
Pharmaceutical distribution	$	198,548,932	$	164,525,782
Retail pharmacy		16,382,277		21,748,464
Manufacturing		19,258,330		19,389,356

Unallocated amounts relating to corporate operations

	Three months ended						Six months ended
	June 30						June 30
	(Unaudited)						(Unaudited)
	2012			2011			2012			2011

Total consolidated revenue	$	61,097,960		$	65,115,748		$	132,343,319		$	123,718,988

Total profit before tax for reportable
segments		8,995,712			12,028,411			21,267,235			21,846,289
Unallocated amounts relating to
operations:
Change in fair value of warrant liabilities		180,177			300,662			137,453			576,044
Share based compensation		(166,006	)		(2,791	)		(305,446	)		(571,314	)
Interest income		4,127			21,708			9,559			21,708
Other income		8,003			72,047			105,532			72,047
Other general expenses		(476,914	)		(576,605	)		(631,353	)		(1,363,643	)
Finance costs		(571	)		(754	)		(774	)		(1,185	)

Income before income taxes	$	8,544,528		$	11,842,678		$	20,582,206		$	20,579,946

unallocated amounts relating to corporate operations, not include in segment information

	June 30,		December 31,
	2012		2011
	(Unaudited)		(Audited)

Assets
Total assets for reportable segments	$	234,189,539	$	205,663,602
Cash and cash equivalents		3,155,636		6,918,847

	$	237,345,175	$	212,582,449

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

China BCT Pharmacy Group, Inc. 10-Q